Design Therapeutics, Inc.
DSGN
Jodie situation report
Design Therapeutics, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 10 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 2 directly disclosed connections are confirming.
- DSGN's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if DSGN's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind DSGN
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
BIIBBiogen Inc.investeeMar 9, 2026 ▾
“Reata Pharmaceuticals was acquired by Biogen in September 2023.”
Depended on by
LRMRLarimar Therapeutics, Inc.competitorMar 19, 2026 ▾
“Other competitors currently developing therapeutics to treat FA include, but are not limited to Design Therapeutics, Lexeo Therapeutics, Neurocrine Biosciences/Voyager Therapeutics, Solid Biosciences and PTC Therapeutics ("PTC").”
Filing peers
No filing peers are available for this name yet.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
DSGN is currently a Follower in the organic co-movement group Mixed Sector Themes. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for DSGN; it is not active in the latest market snapshot.